Canada - engelsk - Health Canada

eugia pharma inc. - ephedrine sulfate - solution - 50mg - ephedrine sulfate 50mg

Irland - engelsk - HPRA (Health Products Regulatory Authority)

roussel laboratories limited - ephedrine hydrochloride prednisone phenobarbital theophylline -

Irland - engelsk - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - pseudoephedrine hydrochloride ; dextromethorphan hydrobromide ; triprolidine hydrochloride - syrup - 30/10/1.25 milligram - pseudoephedrine, combinations

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

max health limited - ephedrine hydrochloride 30 mg/ml - solution for injection - 30 mg/ml - active: ephedrine hydrochloride 30 mg/ml excipient: water for injection - indicated in the treatment of hypotension secondary to spinal anaesthesia in adults.

Canada - engelsk - Health Canada

parke-davis division, warner-lambert canada inc. - phenobarbital; theophylline; l-ephedrine hydrochloride - tablet - 8mg; 118mg; 24mg - phenobarbital 8mg; theophylline 118mg; l-ephedrine hydrochloride 24mg - respiratory smooth muscle relaxants

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical, inc. - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - corphedra is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none r isk summary limited published data on the use of ephedrine sulfate are insufficient to determine a drug associated risk of major birth defects or miscarriage. however, there are clinical considerations [see clinical considerations] . animal reproduction studies have not been conducted with ephedrine sulfate. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown.  all pregnancies have a background risk of birth defect, loss, or other adverse outcomes.  in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. c linical considerations fetal/neonatal adverse reactions cases of potential metabolic acidosis in newborns at delivery with maternal ephedrine exposure have been reported in the literature. these reports descri

USA - engelsk - NLM (National Library of Medicine)

avadel legacy pharmaceuticals, llc - ephedrine sulfate (unii: u6x61u5zeg) (ephedrine - unii:gn83c131xs) - ephedrine sulfate 50 mg in 1 ml - akovaz (ephedrine sulfate injection) is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. none risk summary available data from randomized studies, case series, and reports of ephedrine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. however, there are clinical considerations due to underlying conditions (see clinical considerations) . in animal reproduction studies, decreased fetal survival and fetal body weights were observed in the presence of maternal toxicity after normotensive pregnant rats were administered 60 mg/kg intravenous ephedrine sulfate (12 times the maximum recommended human dose (mrhd) of 50 mg/day). no malformations or embryofetal adverse effects were observed when pregnant rats or rabbits were treated with intravenous bolus doses of ephedrine sulfate during organogenesis at doses 1.9 and 7.7 times the mrhd, respectively [see data] . the

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 15mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - ephedrine hydrochloride - oral tablet - 30mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - ephedrine hydrochloride - oral tablet - 30mg